Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pazopanib
Drug ID BADD_D01687
Description Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Indications and Usage Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
Marketing Status approved
ATC Code L01EX03
DrugBank ID DB06589
KEGG ID D05380
MeSH ID C516667
PubChem ID 10113978
TTD Drug ID Not Available
NDC Product Code Not Available
UNII 7RN5DR86CK
Synonyms pazopanib | GW 786034B | GW786034B | GW-786034B | GW 780604 | GW780604 | GW-780604 | Votrient
Chemical Information
Molecular Formula C21H23N7O2S
CAS Registry Number 444731-52-6
SMILES CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Ascites02.05.04.002; 07.07.01.001; 09.01.05.0030.001175%
Aspartate aminotransferase increased13.03.04.011--
Asphyxia12.01.08.011; 22.02.02.0010.000168%-
Asthenia08.01.01.0010.013823%-
Atrioventricular block02.03.01.0020.000168%-
Azotaemia20.01.01.0010.000168%-
Back pain15.03.04.0050.006223%
Bladder pain20.02.02.0010.000246%-
Blindness06.02.10.003; 17.17.01.003---
Blindness transient06.02.10.006; 17.17.01.0040.000246%-
Blindness unilateral06.02.10.007; 17.17.01.0160.000112%-
Blister12.01.06.002; 23.03.01.0010.004209%-
Blood albumin decreased13.09.01.001---
Blood albumin increased13.09.01.002---
Blood bilirubin increased13.03.04.018--
Blood calcium decreased13.11.01.002---
Blood cholesterol abnormal13.12.01.009---
Blood creatinine increased13.13.01.004--
Blood glucose decreased13.02.02.001---
Blood glucose increased13.02.02.002---
Blood magnesium decreased13.11.01.008---
Blood potassium increased13.11.01.011---
Blood pressure increased13.14.03.005---
Blood pressure systolic increased13.14.03.006---
Blood sodium decreased13.11.01.012---
Blood thyroid stimulating hormone increased13.10.03.006--
Blood urea increased13.13.01.006---
Bone neoplasm15.09.02.001; 16.29.01.0010.000224%-
Bone pain15.02.01.0010.002239%
Bradycardia02.03.02.002---
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 21 Pages